Product Description

Bamlanivimab (LY-CoV**5) is a neutralising monoclonal antibody intended for the treatment of mild to moderate COVID**9.
Drug Name
Bamlanivimab (LY-CoV**5)
Developer
Eli Lilly and Company
Therapy Class
Neutralising monoclonal antibody
Current Indication
Mild to moderate COVID**9
Market Sector
Infectious diseases
Development Status
US FDAs emergency use authorisation (EUA)


Bamlanivimab (LY-CoV**5) received emergency use authorisation for the treatment of mild to moderate COVID**9 in high-risk patients in November ***0. Credit: Eli Lilly and Company.